leadf
logo-loader
viewUrigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain

Urigen Pharmaceuticals, Inc CEO Dan Vickery sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The privately-held company specializes in non-oncological urology treatments.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Manitou Gold's recent drill results at the Goudreau Project in Ontario show...

Manitou Gold (CVE: MTU) CEO Richard Murphy joined Steve Darling from Proactive to share news about the gold exploration company some very interesting projects. One of those projects, Goudreau just returned some very strong drill results. Murphy shares those results and he also talks about the...

22 minutes ago

2 min read